NEW YORK (GenomeWeb) – Biotech firm X-Chem today announced a multi-target collaboration with Pfizer for the potential development of new treatments for inflammatory and orphan diseases.

X-Chem will apply its discovery engine to identify new leads for several of Pfizer's treatment development programs. Pfizer has an exclusive option to license compounds generated from the collaboration. Further details of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.